Journal of Alzheimers Disease & Parkinsonism
Open Access

Abstract

Huntington’s disease (HD) is lethal, hereditary neurodegenerative disorder. The gene and the mutation causing this
monogenetic disorder was identified more than 20 years agobut disease modifying therapies for HD have not been yet
founded. Several preclinical research and large cohort studies like REGISTRY, COHORT or ongoing Enroll-HD significantly
supported understanding of HD and its progression as well as the care of HD patientsbut the identification of targets for
therapeutic interventions and development new chemical entities and advanced therapies incorporating application of DNA
or RNA molecules as therapeutic agents are still ongoing. Disease modifying therapies like huntingtin lowering strategies and
improving huntingtin clearance promoted by posttranslational HTT modifications are most important directions of future
therapies development. Current symptomatic treatment, palliative surgical interventions, physiotherapy and care are available
in highly developed countries for HD patients. It is important to deliver these methods to countries where these are still limited
for HD and develop symptomatic treatment options as they are still only available for HD patients. High number of upcoming
clinical studies/trials in HD and improvement in symptomatic interventions are reasons for hope for HD patients and their
families.

Biography